Online inquiry

IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7093MR)

This product GTTS-WQ7093MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6&IL6R gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000600.5; NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569; 3570
UniProt ID P05231; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7093MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ273MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ5183MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ14465MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ6103MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ11261MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ15260MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ10524MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ8517MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW